Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions director Sujata Tyagi reported a mix of stock awards and tax-related sales. On April 30, 2026, she received an annual grant of 25,344 restricted stock units and 11,296 stock options with a $7.99 exercise price, vesting in one year for continued board service. On May 1, 2026, she sold a total of 13,761 common shares in open-market trades at weighted average prices around the $8–$9 range under a pre-arranged Rule 10b5-1 trading plan to cover taxes from RSU vesting. Following these transactions, she continues to directly hold 100,563 common shares of Emergent BioSolutions.
Emergent BioSolutions director Donald W. DeGolyer reported both equity grants and tax-related share sales. On April 30, he received 25,344 restricted stock units as an annual board grant and 11,296 stock options with a $7.99 exercise price, both vesting one year after grant if he remains on the board.
In connection with RSUs that vested on April 29, he sold a total of 15,481 common shares in open-market transactions on May 1 under a pre-arranged Rule 10b5-1 trading plan to satisfy tax obligations. Following these sales, he directly holds 129,721 common shares, along with the newly granted unvested options.
Emergent BioSolutions director Keith Katkin reported both a sale and new equity awards. He sold 15,481 shares of common stock at a weighted average price of $8.28 per share under a Rule 10b5-1 trading plan to satisfy tax obligations from RSUs that vested on April 29, 2026. On the same date, he received an annual grant of 25,344 restricted stock units for board and committee service, which will vest the day before the one-year anniversary of the grant if he remains on the board. He also received 11,296 stock options with a $7.99 exercise price, expiring April 30, 2033, and reported holding 111,775 shares directly after these transactions.
Emergent BioSolutions Inc. reported that director Marvin L. White received equity compensation on April 30, 2026. He was granted 25,344 restricted stock units for Board and Committee service, each RSU representing one share of common stock upon vesting.
He also received 11,296 stock options, each allowing the purchase of one common share at an exercise price of $7.99 per share. Both the RSUs and options vest on the day prior to the one-year anniversary of the grant date, contingent on his continued board service. After these awards, he directly holds 113,839 common shares.
Emergent BioSolutions Inc. director John D. Fowler Jr. received equity compensation for Board and Committee service. He was granted 25,344 restricted stock units (RSUs), each representing one share of common stock that will vest on the day prior to the one-year anniversary of the grant date, as long as he remains on the board through that date. He was also granted 11,296 stock options to buy common shares at an exercise price of $7.99 per share, expiring on April 30, 2033, which vest on the same one-year schedule. Following the RSU grant, his direct common stock holdings increased to 30,350 shares.
Emergent BioSolutions Inc. reported that director Richard Ronald received equity awards as part of his board compensation. He was granted 25,344 restricted stock units, each representing one share of common stock upon vesting, for Board and Committee service.
He also received 11,296 stock options with an exercise price of $7.99 per share, expiring in 2033. Both the RSUs and options vest on the day prior to the one-year anniversary of the grant date, as long as he remains on the board. After these grants, he directly holds 123,761 common shares.
Emergent BioSolutions director Kathryn C. Zoon reported routine equity compensation and related share sales. On April 30, 2026, she received 25,344 restricted stock units for Board and Committee service and 11,296 stock options with a $7.99 exercise price, both vesting the day before the one-year grant anniversary, subject to continued board service.
On May 1, 2026, she sold a total of 17,202 shares of common stock in open-market transactions at weighted average prices of $8.36 and $8.97 per share under a Rule 10b5-1 trading plan dated May 16, 2025, to satisfy tax obligations from RSUs vesting on April 29, 2026. After these transactions, she directly holds 79,941 common shares.
Emergent BioSolutions director Neal Franklin Fowler received new equity awards as part of his annual board compensation. He was granted 25,344 restricted stock units, each representing one share of common stock that will vest the day before the one-year anniversary of the grant, if he remains on the board.
He also received stock options for 11,296 shares at an exercise price of $7.99 per share, vesting on the same schedule. After these awards, he directly holds 160,847 shares of common stock, plus the newly granted options. These are compensation grants, not open‑market purchases or sales.
Emergent BioSolutions Inc. director and Chairman Zsolt Harsanyi received equity compensation in the form of restricted stock units and stock options. He was granted 25,344 RSUs, each representing one share of common stock upon vesting, and 11,296 stock options with an exercise price of $7.99 per share. Both the RSUs and options vest on the day before the one-year anniversary of the grant date, contingent on his continued service on the board. Following these awards, Harsanyi directly holds 149,076 shares of Emergent BioSolutions common stock.
Williams Paul Anthony reported acquisition or exercise transactions in this Form 4 filing.
Emergent BioSolutions Inc. Senior Vice President, Products Business, Paul Anthony Williams received a grant of 100,111 shares of common stock in the form of restricted stock units. This award was approved by the Compensation Committee on March 2, 2026, contingent on stockholder approval of an amendment to the 2006 Stock Incentive Plan, which stockholders granted on April 29, 2026.
The restricted stock units, granted under the Amended Stock Incentive Plan, vest in three annual installments beginning on the first anniversary of the approval date, assuming continued service with the company. After this grant, Williams directly holds 162,792 shares, and each restricted stock unit represents the right to receive one share of Emergent BioSolutions common stock, subject to adjustment under the grant terms.